Currently, Boehringer Ingelheim BioXcellence™ operates four first-class biopharmaceutical manufacturing facilities: Biberach (Germany), Vienna (Austria), Fremont (USA) and Shanghai (China). All sites offer the entire biomanufacturing technology chain in either mammalian cell culture technology or microbial fermentation.
These multi-product facilities are a testament to Boehringer Ingelheim BioXcellence's™ high-quality leadership, since they enjoy an excellent regulatory track record with both the authorities and customers. We ensure that our customers have flexible access to large-scale global biopharmaceutical manufacturing capacities, thus helping hedge product demand uncertainty while simultaneously offering economies of scale.
All Boehringer Ingelheim manufacturing facilities are certified by the major regulatory authorities such as FDA, EMA and MLHW.